R&D

Our state-of-the-art R&D.
The backbone for your success

IMGL1382s Starogard Gd

State-of-the-art R&D capabilities of a European market leader.

As the B2B hub of the Polpharma Group, Farmaprojects unites the agility and attention you expect, with the state-of-the-art R&D capabilities of a European market leader. 5 R&D centers employing more than 370 people innovating at all product levels. Our experienced IP, Quality and RA teams ensure that you launch early, securely and efficiently: they are the backbone for a successful product launch.

R&D centers

Yes to a B2B innovation powerhouse.

Innovation in B2B starts in our 5 R&D centers, where the Polpharma Group is currently developing more than 260 products, from which more than 100 are FDFs.

R&D centers
0
R&D spending
0 m
development projects in FDF
0 +
patents obtained
0

Intellectual property

Yes to early launches.

Our IP team works hand in hand with R&D to facilitate the earliest possible launch, conducting thorough assessments of IP rights and regulatory exclusivity to mitigate risks and optimize launch timelines. We actively support you by providing tailored reports, follow-ups and up-to-date information relevant to the market, product and geographical area of your interest.

At Farmaprojects, you have highly skilled IP experts with over 15 years of experience in patents at your disposal. You’ll receive unparalleled service through our deep industry knowledge combined with cutting-edge IT tools. Every member of our team is a European Patent Attorney, complemented by additional qualifications such as Spanish Industrial Property Agent and representatives before the Unified Patent Court (UPC).

ABEM7903
ABEM7798

Regulatory affairs

Yes to strategic support.

At Farmaprojects, Regulatory Affairs isn’t just a function; it’s your strategic partner. We’re here to embrace and maximize opportunities while optimizing costs and resources. Our welcoming and multicultural team of experts boasts extensive experience in end-to-end regulatory affairs, operations, and life cycle management on a global scale, meeting the legal requirements and the quality, safety and efficacy that you expect.

Our comprehensive scientific, legal and business knowledge, combined with Farmaprojects’ willpower, will provide you with the best possible regulatory strategy. We empower your company by supporting the decision-making process for a successful product launch in your target markets.

Regulatory Strategy

Regulatory Affairs

Regulatory in numbers

MAs granted globally(1)
0
countries with granted MAs
0 +
global approval rate of MA submissions globally(2)
0 %
different formulations registered globally
0 +

(1) 1,019 MAs granted globally as of 12/04/2024
(2) 92% of global approval rate of MA submissions since we have data

Quality

Yes to comprehensive services.

It is our responsibility to deliver high quality, effective and safe products. Backed by the European market leader Polpharma Group, we continuously invest in innovative technologies to offer you comprehensive analytical services under the highest quality standards.

We meet the requirements of Good Manufacturing Practice (GMP) and manage both the release of EU-products as well as the import and release of non-EU products to be commercialized in EU countries.

Quality Control Services

ABEM7637

Reach out, we’re always listening.